Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of “Hold” from Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have earned a consensus rating of “Hold” from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $9.33.

FULC has been the topic of a number of research analyst reports. HC Wainwright reissued a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Wednesday. Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th.

Fulcrum Therapeutics Stock Up 1.5 %

Fulcrum Therapeutics stock opened at $3.37 on Friday. Fulcrum Therapeutics has a 52-week low of $2.86 and a 52-week high of $13.70. The firm has a market capitalization of $181.77 million, a price-to-earnings ratio of -10.87 and a beta of 2.03. The firm has a 50-day moving average price of $4.12 and a two-hundred day moving average price of $4.61.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.03). Research analysts expect that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

Institutional Trading of Fulcrum Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in FULC. BNP Paribas Financial Markets bought a new position in shares of Fulcrum Therapeutics in the fourth quarter valued at $38,000. China Universal Asset Management Co. Ltd. raised its position in shares of Fulcrum Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after purchasing an additional 4,701 shares during the period. Mariner LLC purchased a new stake in shares of Fulcrum Therapeutics during the fourth quarter valued at $78,000. Walleye Capital LLC purchased a new stake in shares of Fulcrum Therapeutics during the third quarter valued at $59,000. Finally, Intech Investment Management LLC acquired a new position in shares of Fulcrum Therapeutics in the 3rd quarter valued at $62,000. 89.83% of the stock is owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.